INVESTORS & MEDIA
Corporate Governance
| Date | Name | Title | Filing | Type | Shares Traded | Price | Total Held |
|---|---|---|---|---|---|---|---|
| Dec 16, 2014 |
Director, President Regeneron Laboratori
Trans History: 628
|
Director, President Regeneron Laboratori | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 3,264 | $30.63 | 503,264 |
| Dec 27, 2004 |
Director
Trans History: 742
|
Director | Form 5 | Bona fide gift | 22,810 | -- | 504,512 |
| Dec 02, 2015 |
Director, President Regeneron Laboratori
Trans History: 628
|
Director, President Regeneron Laboratori | Form 4 | Open market or private sale of non-derivative or derivative security | 3,625 | $552.54 | 504,601 |
| Aug 17, 2021 |
Director, President & CEO
Trans History: 404
|
Director, President & CEO | Form 4 | Other acquisition or disposition | -- | -- | 504,746 |
| Aug 06, 2021 |
Director, President & CEO
Trans History: 404
|
Director, President & CEO | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 91,430 | $607.51 | 504,746 |
| Aug 27, 2014 |
Director, President Regeneron Laboratori
Trans History: 628
|
Director, President Regeneron Laboratori | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 5,720 | $314.31 | 505,720 |
| Dec 02, 2015 |
Director, President Regeneron Laboratori
Trans History: 628
|
Director, President Regeneron Laboratori | Form 4 | Open market or private sale of non-derivative or derivative security | 4,992 | $551.43 | 508,226 |
| Nov 07, 2016 |
Director, Chairman of the Board
Trans History: 742
|
Director, Chairman of the Board | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 4,394 | $355.52 | 511,332 |
| Dec 02, 2015 |
Director, President Regeneron Laboratori
Trans History: 628
|
Director, President Regeneron Laboratori | Form 4 | Open market or private sale of non-derivative or derivative security | 6,390 | $550.47 | 513,218 |
| May 12, 2020 |
Director, President & CEO
Trans History: 404
|
Director, President & CEO | Form 4 | Open market or private sale of non-derivative or derivative security | 15,542 | $571.49 | 513,449 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.